MedTrace Logo

Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis

NCT00833066 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2011-11-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether the oral administration of grass pollen peptides is safe and effective in the treatment of allergic rhinitis.

Conditions

  • Seasonal Allergic Rhinoconjunctivitis

Interventions

BIOLOGICAL

gpASIT+TM

entero-coated capsules containing 25µg of gpASIT+TM

BIOLOGICAL

Placebo

placebo entero-coated capsules

BIOLOGICAL

gpASIT+TM

entero-coated capsules containing 100µg of gpASIT+TM

BIOLOGICAL

gpASIT+TM

entero-coated capsules containing 400µg of gpASIT+TM

Sponsors & Collaborators

  • BioTech Tools S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-10-31
Completion
2009-11-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00833066 on ClinicalTrials.gov